Results: Hb G-Coushatta showed a clinically significant effect on the measured HbA 1c , particularly when analysis was performed with ion-exchange HPLC methods with short elution times. This interference could be resolved by measuring the HbA 1c using other methods such as HPLC with a long elution time, immunoassay, boronate affinity chromatography, and enzymatic assay. Hb Queens showed a clinically significant difference, defined as a >10% deviation from regression lines, in results from the 2 HPLC methods but not in the other methods. The remaining 5 rare Hb VAR showed different HbA 1c results in the different assays. Conclusion: Hb G-Coushatta, Hb Queens, and other rare Hb VAR can interfere with glycohemoglobin assays, including ion-exchange HPLC methods with short elution times, but the interference can be resolved using other unaffected methods. It is important to identify these Hb VAR through a careful inspection of the chromatograms and apply other noninterfering methods for accurate measurements of the HbA 1c .
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The presence of variant hemoglobins (Hb VAR ) can interfere with some assays used for measuring glycohemoglobin (GHb) (1 ) . Most of these Hb VAR (as many as 800 types thus far) have been recognized in single reports of studies using 1 or 2 HbA 1c determination methods. Nevertheless, studies examining the effects of these variants on various methods have been restricted to a few Hb VAR such as HbS and HbC, which are common in some regional populations (2) (3) (4) (5) .
We previously reported that the Hb VAR and high HbF in the Korean population are not uncommon, with Hb G-Coushatta and Hb Queens being the 2 main Hb VAR found in Koreans (6 ) . Hb G-Coushatta is also one of the most common Hb VAR found in families from the Silk Road region of China and some North American Indian tribes, as well as in Koreans, Japanese, Thai, Turks, Algerians, and Egyptians (6 -10 ) . Hb Queens is the most common ␣-chain variant in people from the Silk Road region of China, and has also been found in Korean, Japanese, Vietnamese, and Thai families (6, 7, 10 ) . However, there are limited data on the effect of these Hb . These variants were identified by direct sequencing of the hemoglobin, alpha 1 (HBA1); hemoglobin, alpha 2 (HBA2); and hemoglobin, beta (HBB) genes, using previously reported protocols (6 ) . The samples were stored below Ϫ70°C when the assay methods were unavailable within 7 days of collection.
We analyzed all the collected specimens using the IFCC primary reference method (PRM) with HPLC-capillary electrophoresis according to approved IFCC protocols (11 ) . This method was chosen as a comparative method owing to its excellent precision and accuracy and minimal interference with common Hb VAR , such as HbS and HbC (11, 12 ) . Furthermore, the values of IFCC PRM accorded very well with those of the boronate affinity method, which has been regarded as unaffected by most Hb VAR (1 ) . To compare the values with other methods, the results of the IFCC PRM were converted into a National GHb Standardization Program (NGSP) value using the following master equation suggested by Hoelzel et al. (12 ) :
NGSP Ϫ HbA 1c ϭ 0.915 (IFCC Ϫ HbA 1c ) ϩ 2.15%.
We also analyzed the specimens with IFCC secondary reference methods (SRM), including Primus Ultra2 A1c and Hemoglobin Variants Analyzer (Ultra2), Roche Unimate HbA 1c test reagents on the Modular system (Unimate), Tosoh G7 in variant mode (G7-VM), and an Arkray Technical Briefs HA-8160 HbA 1c analyzer in diabetic (HA8160-DM) and thalassemia mode (HA8160-TM). Other commercially available assays were also used to examine the GHb concentrations, including Primus PDQ (PDQ), Bio-Rad Variant II System (VII), Bio-Rad Variant II Turbo System (VII-T), Bio-Rad Variant II System in thalassemia mode (VII-TM), Tosoh G7 in standard mode (G7-SM), Roche TinaQuant II reagent on the Modular system (TinaQuant-II), Olympus AU640 System (AU640), Siemens DCA 2000 Analyzer (DCA2000), and Daiichi Norudia HbA 1c test reagent on the Roche Modular system (Norudia). Intermethod calibration differences were corrected as previously reported (5 ) .
We used EP Evaluator Release 7 software (RHOADS) to perform Deming regression analysis on the 2 common Hb VAR (Hb G-Coushatta and Hb Queens) (13 ) . The deviations at 6% and 7% HbA 1c concentrations, at which the examined concentrations of the study samples were distributed, were predicted using the regression lines, and a deviation Ͼ10% of the assessing points (Ϯ0.6% and Ϯ0.7%, respectively) was defined as a clinically significant difference (14 ) .
The chromatogram results obtained with the 7 different HPLC methods for the 2 common Hb VAR are shown in Fig. 1 . Hb G-Coushatta was unrecognizable in VII and HA8160-DM, possibly owing to coelution with the normal peaks, whereas the glycated form of this Hb VAR was eluted separately as a small peak between the S-A1c and A0 peaks in VII-T and G7-SM. Although no abnormal peaks occurred on the VII instrument, we noted blunting of the normal P3 peak and a subtle shift in the retention time of the A0 peak (from approximately 1.78 min to approximately 1.84 min). On the VII-T instrument, the variant peak might be mistaken for a normal P3 peak, which is sometimes observed, but the variant peak had a slightly shorter retention time (approximately 0.72 min) than the P3 peak (approximately 0.77 min; see Table 1 in the Data Supplement that accompanies the online version of this Technical Brief at http://www.clinchem.org/ content/vol53/issue12). Instruments with long elution times, including VII-TM, G7-VM, and HA8160-TM separated Hb G-Coushatta from the other normal peaks.
From the Deming regression analysis, Hb G-Coushatta was predicted to produce clinically significant negative biases in most ion-exchange HPLC methods at both 6% and 7% HbA 1c , with the exception of VII-TM, which showed acceptable results ( Table 1 and see Fig. 1 in the online Data Supplement). This underestimation of the HbA 1c concentrations appears to be due to the coelution of the nonglycated Hb VAR with the normal A0 peak, and the separate elution of the glycated Hb VAR from the normal A1c peak. G7-VM, which separated both the glycated and nonglycated Hb G-Coushatta, did not automatically subtract the variant portion when calculating the HbA 1c . When a manual calculation was performed by subtracting the proportion of the variant peak areas in the denominator according to the manufacturer's instructions, the differences fell into an acceptable mean difference (0.3%), but there were wide variations (from Ϫ1.1% to 1.3%) in each sample (see Table 2 . Hb G-Coushatta was unrecognizable in VII and HA8160-DM and was recognized as only a small glycated peak between the S-A1c and A0 in VII-T and G7-SM, whereas the nonglycated form was separated from the other normal peaks in VII-TM, G7-VM, and HA8160-TM. The nonglycated form of Hb Queens was eluted discretely in all instruments except G7-SM. the 2 boronate-affinity methods and 1 new enzymatic assay, were predicted to have good performance.
A few case studies of patients with Hb G-Coushatta have obtained results in accordance with the present data. One study of a Japanese Hb G-Coushatta family found that unexpectedly low HbA 1c values were obtained with an ordinary HPLC method (method unknown) compared with the values from a latex agglutination immunoassay and high-resolution weak cation-exchange column chromatography (15 ) . Another study found 1 case of a lower HbA 1c concentration result obtained with the Daiichi Hi-AUTO A1c HA-8150 HbA1c analyzer (2.7%) than with the DCA2000 (4.7%) and electrospray mass spectrometry (5.0%) (16 ) .
Hb Queens is another common Hb VAR in the Korean population. Hb Queens was eluted discretely on the 3 Bio-Rad instruments (VII, VII-T, and VII-TM) in the S-window. This Hb VAR was also separated using G7-VM, HA8160-DM, and HA8160-TM, but was indistinguishable in G7-SM (Fig. 1) . Hb Queens was expected to produce no clinically significant effects with most test methods except for G7-SM and VII, for which regression lines predicted a considerable underestimation and slight overestimation, respectively ( Table 1) .
Chromatograms of the 5 rare Hb VAR are shown in Fig.  2 of the online Data Supplement. Hb G-Hsi-Tsou was separated in all instruments. Hb Ube-4 could not be differentiated in either of the 2 modes of the G7 instrument. Hb G-Waimanalo was separated with all methods except for G7-SM. Hb Inglewood was recognized only in VII and VII-TM (VII showed only a small peak between A1c and A0). Hb Bologna-St.Orsola had a retention time similar to the A1c peak, a result that led to a gross overestimation of the HbA 1c concentrations in VII and VII-T, whereas only a slight increase of the L-A1c peak was observed in G7-SM. The 5 rare Hb VAR showed variable degrees of deviation from the IFCC PRM results, but the number of samples was not enough to draw conclusions about possible interference (see Table 2 in the online Data Supplement). Hb Bologna-St.Orsola, which is a rare Hb VAR with increased oxygen affinity and compensatory erythrocytosis, showed significant differences in all ion-exchange HPLC methods, even when it was separated from the other normal peaks (as in VII-TM, G7-VM, HA8160-DM and HA8160-TM). It is possible that the glycation rate or erythrocyte lifespan of this Hb VAR might be different from the normal Hbs. Theoretically, even methods such as an immunoassay, boronate-affinity, and the IFCC PRM, which provide analytically valid GHb results, may not provide an accurate assessment of the mean plasma glucose with rare Hb VAR such as Hb Himeji, because of the differences in glycation rates or erythrocyte life spans (16, 17 ) . Interestingly, an abnormal chromatogram pattern in this patient suggested the presence of Hb VAR and helped identify the cause of the unexplained erythrocytosis through a subsequent genetic study.
Comparison studies showed that the common Hb VAR as well as some rare Hb VAR in Koreans can interfere with the different HbA 1c methods, particularly those performed on HPLC instruments with a short elution time. This interference can be resolved by measurement with unaffected methods such as HPLC with a long elution time, immunoassay, boronate affinity chromatography, and enzymatic assay. The chromatograms of the ion-exchange HPLC methods also showed variable patterns, a finding that highlights the need for a careful inspection of the chromatograms, particularly for analysis of samples suspected of having an Hb VAR or when an unexpected result is obtained. Overall, it is impor- 
Background:
The specific detection of a minor population of mutant DNA molecules requires methods of high specificity and sensitivity. While the single-allele base extension reaction (SABER) was shown to be useful for the detection of certain beta-thalassemia mutations, we encountered problems with false positivity during development of SABER for the noninvasive prenatal diagnosis of the hemoglobin E (HbE) disease. Systematic optimization resulted in an alternative protocol, the allele-specific base extension reaction (ASBER). Methods: An artificial model was established by mixing genomic DNA of HbE carriers and normal individuals. Effects of terminator concentration and annealing temperature on the nonspecificity of SABER were then studied. The use of a single relevant terminator and the other 3 types of dideoxynucleotide as competing terminators were also compared in the development of the ASBER protocol. Thirteen cases of HbE-susceptible pregnancies were tested to compare the SABER and the ASBER protocols. Results: Decreasing the single relevant terminator concentration and increasing the annealing temperature in SABER were found to improve specificity. The use of the other 3 types of dideoxynucleotide as competing terminators was shown to offer better detection sensitivity than a single terminator in ASBER. Genotyping results were all correctly determined by ASBER, except one false-negative detection (sensitivity: 80%, specificity: 100%). Conclusions: An alternative mass spectrometry-based protocol for noninvasive prenatal diagnosis, ASBER, has been successfully developed to allow the detection of a minor DNA population with a point mutation.
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The discovery of circulating fetal nucleic acids in maternal plasma has opened up exciting possibilities for noninvasive prenatal diagnosis (1, 2 ) . The recent development of Clinical Chemistry 53, No. 12, 2007 the mass spectrometry-based single-allele base extension reaction (SABER) protocol has enabled sensitive differentiation of fetal-specific alleles down to a single-nucleotide level (3) (4) (5) . In this report, we intended to develop a mass spectrometry-based method for the noninvasive prenatal diagnosis of the hemoglobin E (HbE) mutation. Unexpectedly, the lack of specificity of SABER for the HbE mutation was discovered during assay development, and systematic optimization on an artificial model has been carried out. This development has resulted in an alternative protocol, the allele-specific base extension reaction (ASBER).
HbE disease is an autosomal recessive hemoglobinopathy caused by a (GAG3 AAG) missense mutation in codon 26 of the ␤-globin gene (6 ) . It is the most common thalassemic hemoglobinopathy in Southeast Asia (7 ). Although homozygotes of HbE are mildly affected by the mutation, compound heterozygotes of the HbE and the ␤-thalassemia mutation will result in severe anemia (HbE/␤-thalassemia). Therefore, detection of the HbE mutant allele is critically important in the prenatal diagnosis of thalassemia major in Southeast Asia. In noninvasive prenatal diagnosis of HbE, the absence of the paternally transmitted fetal HbE mutant allele in the plasma of a pregnant female carrier of a ␤-thalassemic mutation negates the fetal inheritance of HbE/␤-thalassemia. Theoretically, this suggests that 50% of invasive procedures are unnecessary and can thus be avoided.
All samples in this study were collected with informed consent, and approval was granted by the institutional ethics committee. Venous blood (6 mL) was collected into EDTA tubes from each couple referred for prenatal diagnosis. Plasma and buffy coat were harvested from blood samples after a 1st centrifugation at 1600g for 10 min and a further microcentrifugation of plasma aliquot at 16 000g for 10 min as previously described (8 ) . DNA was extracted from buffy coat and 800 L of plasma by a Nucleon Blood DNA Extraction Kit (GE Healthcare) and a QIAamp Blood Mini Kit (Qiagen) with elution volume of 50 L H 2 O, respectively, according to the manufacturers' recommendations.
The principle of standard homogenous MassEXTEND (Sequenom) and SABER protocols have been described previously (3 ) . HotStar Taq polymerase (Qiagen) was used in the PCR at a final volume of 25 L, containing 10 L of plasma DNA and 0.2 mol/L PCR primers (Integrated DNA Technologies). The thermal profile was 95°C for 15 min for hot start, 45 cycles of denaturing at 95°C for 20 s, annealing at 58°C for 30 s, and extension at 72°C for 1 min, followed by a final incubation at 72°C for 3 min. PCR products were then treated with shrimp alkaline phosphatase (Sequenom) for 40 min at 37°C to remove unreacted dNTPs. Base extension reaction was carried out with thermosequenase (Sequenom) on 10 L of shrimp alkaline phosphatase-treated PCR product in a final reaction volume of 14 L, with 1.54 mol/L of the extension primer (Integrated DNA Technologies) and a terminator mix of dideoxy/deoxynucleotides, each at 64 mol/L. The thermal profile consisted of 94°C for 2 min, followed by a rapid thermocycling for 75 cycles at 94°C, 52°C, and 74°C, all for 5 s. Products were then analyzed by the MassARRAY™ Analyzer Compact Mass Spectrometer (Brucker), a MALDI-TOF system. Details of the PCR primers, termination mix, and extension primers are listed in the Data Supplement that accompanies the online version of this Technical Brief at http://www.clinchem. org/content/vol53/issue12.
Thirteen HbE-negative pregnant participants (gestational age: 16 -22 weeks) with male partners being HbE carriers were recruited. Genotypes of the couples and the fetuses were confirmed by analysis of buffy coat and cord blood samples, respectively, by the standard homogenous MassEXTEND protocol. Five of the fetuses were shown to be HbE positive.
Genotyping results of the SABER protocol on maternal plasma showed nonspecificity (see Fig. 1 in the Data Supplement). All 8 informative-negative pregnancies were misclassified as positive. To evaluate the important analytical parameters for the nonspecificity of SABER, an artificial model was established. Genomic DNA of a male HbE carrier was mixed with wild-type maternal genomic DNA to mimic the plasma DNA of an affected pregnancy. Direct dilution of wild-type maternal genomic DNA was used to mimic plasma DNA of normal pregnancy. Systematic evaluation revealed that the terminator concentration and the annealing temperature in the base extension reaction were critical for the reduction of falsepositive detection in SABER. A 50-fold dilution of the standard terminator concentration and annealing temperature at 66°C were shown to be optimal for both specific and sensitive detection of the HbE mutation in the artificial model (Table 1) . We explored the development of an alternative protocol, ASBER. The 3Ј end of the extension primer for ASBER was engineered to be complementary to the fetal mutant allele. Hence, primer extension of the maternal wild-type allele would be inhibited by 3Ј-primer-template mismatch (Fig. 1A) . Initially, the use of a single relevant terminator (ddA only) at standard concentration also revealed nonspecificity (data not shown). Thus, terminator dilution and the introduction of competing terminators (ddA, ddC, ddG, and ddT, each at 64 mol/L) in the ASBER protocol were evaluated. Both the use of competing terminators and 20-fold dilution of the relevant terminator were found to provide specific genotyping results. However, the use of competing terminators appears to offer better detection sensitivity on the artificial model with different percentage mix of mutant DNA (Fig. 1B) . The design of ASBER with competing terminators was adopted to reanalyze the 13 maternal plasma samples, and the fetal genotypes were all correctly determined except 1 case of false-negative result.
In this study, we have shown that for certain mutational context, SABER might generate nonspecific results due to incorporation of the single terminator in the extension reaction mixture despite it being noncomplement to the template PCR product. Although the mechanism behind this nonspecificity or misincorporation is still unclear, we hypothesize that the intrinsic specificity of SABER is a subtle balance between the fidelity of the polymerase and the degree of excess of the single relevant terminator in the primer extension reaction mixture (9 ) . The lower the polymerase fidelity and the higher the terminator concentration promote misincorporation. Based on this reasoning, optimization can be achieved by adjusting the terminator concentration as described above (Table 1A) . Others have shown that the polymerase fidelity could be improved by using a proofreading polymerase (9 ) . However, this method did not offer any improvement in the specific detection of the trace amount of fetal DNA in maternal plasma in our preliminary findings (data not shown). On the other hand, we showed that nonspecificity of SABER was reduced by increasing the annealing temperature for base extension (Table 1B) . This result might be because the environment becomes less favorable for misincorporation of the noncomplementary terminator.
To overcome the intrinsic tendency of terminator misincorporation in SABER, we explored and developed ASBER based on the principle of allele-specific primer extension, which has been reported to offer successful mass spectrometry-based mutation genotyping (10, 11 ) . However, such design has not been applied to specific fetal allele detection in noninvasive prenatal diagnosis. Compared with previous studies (10, 11 ) , specific priming of the fetal-specific allele in noninvasive prenatal diagnosis is less favorable due to the overwhelming background of maternal allele and the lack of priming competition from alternative allele-specific primer. Yet we expect better specificity in ASBER than the conventional allelespecific PCR (12 ) , because the ASBER extension products would not serve as templates for further amplification. Thus, a misprimed ASBER product, if it occurs, would not be exponentially propagated. Nevertheless, false-positive detection is also detectable in ASBER with the single relevant terminator and therefore required optimization. False-positive detection was not observed in ASBER with competing terminators. This finding further suggested that an overdominance of any single terminator in the extension mixture promotes misincorporation. Further comparison of detection sensitivity of the 2 ASBER protocols shows that improving specificity by reduction of the fractional concentration of a terminator (i.e., inclusion of 3 other types of dideoxynucleotide as competing terminators) is better than dilution of the relevant terminator (Fig. 1B) .
Reanalysis of the 13 pregnancies at risk for HbE/␤-thalassemia with the ASBER protocol showed substantial improvement in specificity compared with the SABER protocol, with 1 false-negative result. The diagnostic performance of the HbE ASBER assay needs to be confirmed with larger-scale studies.
In summary, we have successfully developed ASBER, which confers advantages in terms of specificity and sensitivity over SABER for the detection of the HbE mutation. Using this approach, noninvasive prenatal diagnosis of the HbE mutation has been achieved with a specificity of 100% (8 of 8) and a sensitivity of 80% (4 of 5). To further improve the sensitivity of the assay, potential fetal allele enrichment steps-for example, PCR clamping by PNA probe and size fractionation-can be included (13 ) . We speculate that the application of the ASBER protocol can be extended to other fields of circulating nucleic acids, for instance, detection of circulating tumorspecific DNA in cancer patients such as KRAS point mutations (14 ) and detection of circulating donor-specific DNA in transplant recipients (15 ) . Background: Working toward a goal of total laboratory automation, we are automating manual activities in our highest volume laboratory section. Because half of all specimens arriving in this laboratory section are frozen, we began by developing an automated workcell for thawing frozen specimens and mixing the thawed specimens to remove concentration gradients resulting from freezing and thawing. Methods: We developed an initial robotic workcell that removed specimens from the transport system's conveyor, blew high-velocity room temperature air at the tubes, mixed them, and replaced them on the conveyor. Aliquots of citrated plasma were frozen with thermocouples immersed in the tubes, and thawing times and temperatures were monitored. Completeness of mixing of thawed specimens was studied by careful removal of small aliquots from the uppermost layer of the upright tubes without disturbing tube contents and analysis of total protein and electrolytes. Results: High velocity ambient air aimed directly at tubes ranging from 12 ؋ 75 to 16 ؋ 100 mm brought specimens to room temperature in a maximum of 23 min. Adequate mixing of the specimens by the workcell's robot required only 2 approximate 126°move-ments from an upright starting point, a surprising observation, because laboratorians are usually trained to mix 10 or 20 times. We also observed that, in a frozen overfilled tube, resulting analyte concentrations will be lower because more concentrated solutes leak from the tube. Conclusions: A high-throughput, automated thawing and mixing workcell was successfully built, validated, and installed on our automated transport and sorting system.
Our laboratory is a high-volume esoteric reference laboratory, accepting approximately 25-30 000 specimens per day. One of our largest laboratory sections, the Automated Core Laboratory, receives approximately 25% of that daily volume, performing more than 140 different chemistry, immunoassay, and specific protein tests, emphasizing cancer antigens, endocrine testing, and urine chemistry, but not routine serum chemistry. More than half of these 6 -7000 specimens per day are frozen. The laboratory has been thawing them manually at room temperature (to prevent degradation of labile analytes) by blowing air from an ordinary electric fan at batches of tubes, a process requiring more than 1 h to assure complete thawing. The specimens were then mixed by manually inverting the tubes 10 times, before decapping for the various analyses.
Our long-term objective for this laboratory section is to interface analyzers to our automated transport and sorting system to achieve total laboratory automation and to automate other manual activities such as inspecting for adequate specimen volume and for the presence of interfering substances as indicated by hemolysis, lipemia, and icterus. The development of some form of automated workcell for rapidly thawing specimens at room temperature and mixing the thawed specimens was a 1st step toward our overall automation objective. We are not aware that such a robotic system has previously been built or described.
Our design intention with the workcell was to leave the specimen tubes in their track carriers (see Supplemental Fig. 1 that accompanies the online version of this Technical Brief at http://www.clinchem.org/content/vol53/ issue12). Therefore, we sought to aim the thawing air directly at the tubes in the carrier through a slit normally used for reading bar codes. We developed an experimental apparatus with which we could evaluate a variety of nozzle designs that would direct air into the carrier slit (Supplemental Fig. 2 ). This design included thermocouples to monitor the thawing times of the tubes. Initially, thawing of frozen water was evaluated, but later, when the conditions of air flow and nozzle design had been established, we tested the system with specimens of out-of-date blood bank plasma. These studies (shown in Supplemental Fig. 3 ) indicated that a nozzle shaped as a small brass plug with a 2-mm orifice on a beveled edge (Supplemental Fig. 4 5 ) uses an HP3XFC articulated 6-axis robot to remove specimen carriers from the track and place them on the deck in holders that prevent them from falling over, even with high velocity air blowing at them. A 10-hp, 480-volt, 60-cycle compressor directs the air into a plenum, which comprises the deck of the system. A total of 760 brass nozzles as described above are attached to the plenum, each designed to aim at the tube directly in front of it through the slit in the carrier. A variable frequency drive regulates compressor speed to maintain constant pressure in the plenum, thus optimizing the air flow from each nozzle. The number of nozzles in the deck design was based on the reach of the robot combined with a target workcell throughput speed of at least 1000 specimens per hour. The robot was fitted with a custom-designed pneumatic tool that grasps up to 10 carriers, with tubes, at a time for transfers between the conveyor system and deck and for mixing. This tool also uses pneumatic pin cylinders that press tightly against the top of each tube cap. In case a tube is capped with a push-top instead of a screw cap, the pin cylinders assure that the cap will not loosen during mixing and possibly leak.
The completed workcell was subjected to a rigorous validation study. In our thawing studies, most of the 760 locations on the thawing deck were populated with labeled tubes of frozen water, except that in key locations we placed plasma specimens in labeled tubes with temperature-recording thermocouples and surrounded those tubes with other plasma specimens in labeled tubes. The intent was to have a full deck of 760 frozen specimens to determine their impact on the plenum temperature and the overall thawing rate. In repetitive studies we then adjusted the air flow from the compressor by varying the compressor speed, seeking to balance an optimal thawing time against generation of excess heat and compressor noise. Compressing air generates heat (1 ) , and, at higher compressor speeds (higher air flow), the plenum became warmer than desired for thawing of specimens, as determined by baseline temperature measurements. The results of one of these thawing studies with different air flows are shown in Fig. 1 . All of the thermocouple temperature readings were above 20°C in 23 min or less. These rapid thawing times were achieved with a combination of high air flow (0.0000333 m 3 /s, or 0.0333 L/s, per specimen) and directing the air flow into the slit of the carrier so that it wrapped around the tube, thawing it from all sides. We postulated that, without the transport carrier, the air would simply have deflected off the front of the tube, and the back of the tube would not have thawed as quickly. This air flow was obtained with the variable frequency drive set at 45%, which delivered an alternating current frequency of 27 cycles per second.
The formation of concentration gradients in serum, urine, and other frozen specimens after the specimens are thawed is known (2, 3 ) , and thawed specimens must be well mixed before they can be analyzed. Most laboratorians are trained to mix specimens 10 -20 times before testing, but we were unable to find a published reference The temperatures in all tubes reached 20°C in 24 min or less in this study at a variable frequency drive setting of 40% (24 cycles per second). The variable frequency drive setting chosen for routine operation was 45% (27 cycles per second), which gave slightly greater air flow, with all tubes at or above 20°C in 23 min or less. recommending any particular number of mixes. We designed the workcell's 6-axis robot to perform the mixing by maintaining the specimens over a fixed location, so that a stainless steel pan could be positioned to catch drips from any leaking specimens. This design, coupled with the design of the pneumatic tool and its pin cylinders limited the range of rotation of the tubes to 126°in either direction. The resulting mixing pattern consisted of a rotation of approximately 126°to the left from an upright starting position, return to upright, then 126°to the right, and return to upright. A single 126°tilt and return to upright constitutes 1 mix cycle in this discussion. We evaluated 0, 2, 4, up to 12 mix cycles each with 5 different replicate expired blood bank plasma specimens of 4.5 mL using our standard false bottom tube. The tubes were thawed on the workcell deck, but without the air blowing, to avoid any vibration or shaking of the tubes. After the tubes had thawed, we carefully sampled 200 L from the uppermost layer of each tube. The 1st set of replicates was sampled without robotic mixing, the 2nd set was sampled after 2 mix cycles, the 3rd set after 4 mix cycles, and so on. The aliquots were analyzed for albumin, sodium, potassium, and chloride on a Modular P analyzer (Roche Diagnostics) and compared to 5 replicates of unfrozen plasma that served as baseline or expected values. The results are shown in Table 1 . After only 2 mix cycles (2 elevations to 126°followed by return to upright), the levels of all 4 analytes were indistinguishable from the baseline levels. This result was surprisingly fewer than we had expected based on experience. However, because human mixing motions may not duplicate the uniform speed and angles of our programmed robot (approximately 2 seconds to tilt 126°and return to upright), we are not recommending that laboratorians reduce their specimen mixes.
Knowing that an air bubble was required to achieve specimen mixing, we evaluated overfilling tubes with plasma in an attempt to determine the minimum size of air bubble necessary for adequate mixing. The volume of water expands approximately 9% when it is frozen (4 ). Furthermore, if a tube is filled too full and leaks due to this expansion, specimen solutes (minerals, proteins, etc.) preferentially squeeze through the cap threads, as has been reported for frozen, overfilled standard solutions (5 ) and for frozen, overfilled serum and urine specimens (2 ), and leaked specimens will be unacceptable for testing because the concentrations of analytes will have changed. We also learned that the minimum size of air bubble to facilitate mixing was 1.0 mL, which was sufficiently below the top of the tube to prevent leakage during freezing.
In summary, we designed, validated, and installed an automated thawing and mixing workcell, which is connected to our automated transport system and has a throughput to thaw and mix Ͼ1000 specimens per hour. The 6-axis robot appears able to effectively mix specimens with fewer mixes than routinely taught to laboratorians. Overfilled specimens that leak when frozen are unacceptable for laboratory analysis. Hemophilia A (HA) is a coagulation disorder caused by a lack of normal coagulation factor VIII (FVIII) activity (1 ) . This disease is caused by mutations in the coagulation factor VIII, procoagulant component (hemophilia A) (F8) gene, which encodes FVIII and is located at Xq28. F8 is a large gene, comprising 26 exons across 186 kb, and produces a 9-kb mRNA transcript. All exons are small (69 -262 bp) except exon 14, which is 3.1 kb.
Approximately 45% of severe HA cases are the result of a large inversion that disrupts the F8 gene in intron 22, and a further 1%-5% are caused by an inversion affecting intron 1. In the remaining severe cases, and in cases of mild or moderate HA, a single-base substitution, small insertion, or deletion is usually the causative mutation. Such mutations create either missense, nonsense, or frameshift mutations, or affect consensus splice sites [reviewed in (2 ) ]. Many such variants have been reported in HA patients, and more than 900 different mutations have been described (3 ) .
Many hematology services now offer genetic screening to identify the F8 gene mutation in their HA patients. This information allows identification of carrier females, prenatal testing for affected pregnancies, preimplantation genetic diagnosis, and in some cases prediction of the likelihood of FVIII inhibitor production in HA patients receiving prophylactic FVIII treatment (2 ) .
Genetic screening of HA patients who do not have either the intron 1 or intron 22 inversions is problematic because of the size of the F8 gene and the variety of mutations that can occur. Before capillary-based DNA sequencing platforms were widely available it was not practical to sequence all 26 exons, so mutation-scanning strategies such as single-strand conformational polymorphism analysis were used (4 ) . A more sensitive technique, denaturing HPLC (dHPLC), has also been used successfully for F8 mutation scanning (5 ) . In our laboratory we have used dHPLC combined with DNA sequencing to identify 20 different F8 gene mutations in 28 HA patients we have analyzed (6 ). Although we have found dHPLC to be a sensitive scanning method, it is a low-throughput technology and has many ongoing costs. Likewise, DNA sequencing of the F8 gene is time-consuming and expensive.
High-resolution melting analysis represents the next generation of mutation scanning technology and offers considerable time and cost savings over both dHPLC and sequencing. This closed-tube assay is performed on amplicons post-PCR. In the presence of a saturating doublestranded DNA-binding dye, amplicons are slowly heated until fully denatured while the fluorescence is monitored (7 ) . Amplicons heterozygous for a sequence variant yield altered melting curves compared with normal control samples. High-resolution melting analysis has recently been tested in a variety of clinical mutation-scanning applications and shown to be a sensitive and cost-effective technique (8 -14 ) .
In this study we assessed whether 20 different F8 gene mutations, located across 13 exons, could be detected by high-resolution melting analysis. These are mutations we have previously identified by dHPLC and DNA sequencing during our F8 gene-screening program (6 ) . For each mutation we assessed whether the melting curve of the heterozygous amplicon differed from that of the corresponding normal amplicon to evaluate whether a melting analysis screen of the F8 gene would detect the variant. We tested 2 different platforms-the Roche LightCycler 480 (LC480) and the Idaho Technology LightScanner.
Genomic DNA from 20 male HA patients, each with a different F8 gene mutation, was mixed with an equal amount of DNA from a healthy male control. Because males are hemizygous for the F8 gene, this mixing is necessary to ensure the amplified exon is heterozygous for the F8 mutation, which is a requirement for detection by melting analysis. Each mixed sample, and a mixed normal control, was amplified using primers targeting only the F8 exon where the mutation is located. We used primer sets previously optimized for dHPLC by Oldenburg et al. (5 ) , because the requirements of amplicons for melting analysis are likely to be similar to those for dHPLC. Samples were amplified in duplicate 15-L PCRs using the LightCycler 480 Genotyping Master PCR mixture (Roche), in the presence of 1ϫ LCGreen PLUS (Idaho Technology), 0.5 mol/L forward and reverse primers, and 50 ng DNA template. The thermal cycling protocol was as follows: polymerase activation (95°C for 10 min); touchdown cycling step [5 cycles of: denaturation at 95°C for 20 s, annealing at 61°C for 20 s (decreased by 1°C per cycle), extension at 72°C for 20 s]; amplification (40 cycles of: denaturation at 95°C for 20 s, annealing at 56°C for 20 s, extension at 72°C for 20 s); and a final extension (72°C for 5 min). The touchdown cycling step was included to improve specificity of the PCR because LCGreen PLUS is known to increase the melting temperature of primers by 2-4°C (15 ). For samples analyzed on the LC480, the melting step was appended to the amplification step; samples melted on the LightScanner were amplified on the LC480 as above, then transferred to the LightScanner for the melting analysis.
To analyze melting data on both the LC480 and the LightScanner software, melting curves were normalized by defining regions in the pre-and postdenaturation parts of the curve, and the value was set for the melting temperature shift adjustment. Output plots are in the form of normalized temperature-shifted melting curves that show the decrease in fluorescence (Fl) against increasing temperature, and difference curves that show the difference in fluorescence (⌬Fl) between the melting curves of the mutation sample and the normal control, against temperature. The difference curves provided the best resolution to differentiate mutation and normal samples, with the amplitude of the peak (⌬Fl max ) recorded as a measure of the resolution. On the basis of the observed variation in 4 normal controls (see Figs. 1-3 in the Data Supplement that accompanies the online version of this Technical Brief at http://www.clinchem.org/content/ vol53/issue12), we considered that a ⌬Fl max value of at least 5 on the LC480, which is equivalent to 0.05 on the LightScanner, was sufficient resolution to distinguish the mutant sample from the normal control, although the shape of the curve is also an important consideration and may indicate the presence of a variant even if ⌬Fl max Յ 5/0.05.
Analysis of the data indicated that 18 of 20 F8 gene mutations included in this study were detected by melting analysis on both LC480 and LightScanner platforms, with ⌬Fl max values of at least 5/0.05 (Table 1) . The variants F1775L (c.5380TϾC, exon 16) and c.6901-2AϾG [intron 25 (exon 26 amplicon)] had ⌬Fl max of Ͻ5/0.05, indicating a lower confidence in the ability of the melting analysis to resolve the mutant sample from the normal controls (see Figs. 1 and 3 in the online Data Supplement). Even when PCR products from the mutant samples were mixed with products from normal DNA post-PCR, the resolution of these samples was still poor (see Figs. 4 and 5 in the online Data Supplement).
Data for the melting analysis of F8 exon 23 variants on the LightScanner is shown in Fig. 1 . These curves are representative of the other samples in the study listed in Table 1 and show the difference curve for each variant (in duplicate) derived using the normal sample melting curve as a reference, which appears on the difference plot as the baseline. Each exon 23 variant has a distinct curve profile, indicating this technique can distinguish different variants from each other, as well as from the normal sample. Melting curves for these exon 23 variants on the LC480 are shown in Fig. 2 of the online Data Supplement, along with 4 controls to indicate the variability in normal samples.
The LC480 and LightScanner platforms performed similarly overall, although each has strengths and weaknesses. The LC480 is a thermal cycler, so samples for melting analysis can be amplified on this machine, with the melting step appended to the PCR protocol. The amplification of samples can be monitored in real time, because LCGreen PLUS fluorescence is proportional to the amount of double-stranded DNA in the PCR, and any samples in which amplification failed can be removed from the melting analysis. The LightScanner performs only the melting step, but in our hands gave greater consistency between replicate samples. Both machines use a 96-well plate format (with the option for a 384-well format), enabling rapid throughput of samples.
In summary, high-resolution melting analysis is a powerful and cost-effective option for mutation scanning of the F8 gene. The sensitivity of this technique is comparable to dHPLC, and it offers advantages in the speed and cost of analysis. To support the F8 mutation-scanning screen in the clinical setting, DNA sequencing of amplicons in which a putative mutation (or polymorphism) was detected can be used to confirm and identify the variant and to rescreen any samples in which no mutations were detected across all F8 exons. In this context, scanning by high-resolution melting analysis is an ideal technology because it is rapid, economical, and capable of detecting most mutations (90% in this study). Mutations not detected by the melting analysis screen would be identified by subsequent sequencing of all F8 exons for that sample. The upper chart shows the normalized temperature-shifted melting curves [using the default melting-temperature shift adjustment (0.05)], and the lower chart shows the difference curves, derived using the normal sample as the baseline. Data for duplicate samples for each variant is shown. For data from the LC480, see Fig. 2 in the online Data Supplement.
